Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 4/20 | 0.35 |
| ▸ | GRIK2 | Q13002 | 4/20 | 0.35 |
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
| ▸ | FNTB | P49356 | 1/20 | 0.32 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2031192 | 1.00 | SLC1A3 (0.48) | SLC1A3SLC1A2SLC1A1TDP1TP53 | |
| SCHEMBL8101229 | 1.00 | SLC1A3 (0.48) | SLC1A3SLC1A2SLC1A1TDP1TP53 | |
| SCHEMBL8096822 | 1.00 | SLC1A3 (0.48) | SLC1A3SLC1A2SLC1A1TDP1TP53 | |
| SCHEMBL2035310 | 1.00 | SLC1A3 (0.48) | SLC1A3SLC1A2SLC1A1TDP1TP53 | |
| SCHEMBL2031190 | 1.00 | SLC1A3 (0.48) | SLC1A3SLC1A2SLC1A1TDP1TP53 | |
| SCHEMBL2035309 | 1.00 | SLC1A3 (0.48) | SLC1A3SLC1A2SLC1A1TDP1TP53 | |
| SCHEMBL4452075 | 0.93 | SLC1A3 (0.43) | SLC1A3SLC1A2SLC1A1TDP1TP53 | |
| SCHEMBL4452078 | 0.93 | SLC1A3 (0.43) | SLC1A3SLC1A2SLC1A1TDP1TP53 | |
| SCHEMBL9575678 | 0.91 | GRIK1 (0.47) | SLC1A3SLC1A2SLC1A1TDP1GRIK1 | |
| SCHEMBL9858552 | 0.91 | GRIK1 (0.47) | SLC1A3SLC1A2SLC1A1TDP1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011070459-A1 | PROCESS FOR ENANTIOMERICALLY PURE 8-ARYLOCTANOIC ACIDS AS ALISKIREN | CarboDesign LLC (US) | 2011-06-16 | — | — | WO | disclosed |
| US-20110137047-A1 | Process for enantiomerically pure 8-Aryloctanoic acids as Aliskiren | CarboDesign LLC (US) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110137047-A1 | Process for enantiomerically pure 8-Aryloctanoic acids as Aliskiren | REN, CYP51A1, AGTR2 | SLC1A3 2665/4885SLC1A2 2575/4885SLC1A1 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.